scholarly journals Diffuse large B-cell Lymphoma mimicking as cholangiocarcinoma in a young male presenting with obstructive jaundice

2021 ◽  
Vol 5 (1) ◽  
pp. 039-040
Author(s):  
Danish Muhammad ◽  
Khan Shoaib Ahmed ◽  
Samoon Dilnawaz ◽  
Majid Zain ◽  
Hanif Farina ◽  
...  
Keyword(s):  
Bile Duct ◽  
Obstructive Jaundice ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

The involvement of bile duct in lymphoma is considered to be very rare and is usually a sequela of a disseminated disease [1]. In contrast to secondary involvement, primary non-Hodgkin’s lymphoma arising from the bile duct is extremely rare and presents with obstructive jaundice [2,3]. Non-Hodgkin’s lymphoma (NHL) accounts for 1% - 2% of all cases of malignant biliary obstruction [4]. Hepatobiliary involvement by malignant lymphoma is usually a secondary manifestation of systemic lymphoma. The first case of Non-Hodgkin lymphoma arising from bile duct was described by Nguyen in 1982 [5]. Most common extra nodal involvement of NHL is abdomen. Although, involvement of the stomach, pancreas or common bile duct is not common [6]. We present to you a case of 31year old male who presented to us with obstructive jaundice and was later diagnosed as Diffuse Large B-Cell lymphoma.

Diffuse Large B-Cell Lymphoma of the Ankle

2010 ◽  
Vol 100 (6) ◽  
pp. 505-510 ◽  
Author(s):  
Mark J. Mendeszoon ◽  
Kyle R. Wire
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Surgical Excision ◽  
Hodgkin's Lymphoma ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

The most common type of non-Hodgkin’s lymphoma is the B-cell type. We report herein a type of B-cell lymphoma in an adult ankle. A 63-year-old woman presented with a painful growth on the anteromedial aspect of her right ankle that was later diagnosed as a form of non-Hodgkin’s lymphoma. Clinically, the single mass appeared bluish in color, painful on palpation, and warm to the touch. The overlying skin was friable, and the lesion did not transilluminate. Histopathologic examination revealed a diffuse large B-cell lymphoma of germinal center origin on surgical excision. This case report focuses on the clinical presentation, surgical intervention, and overall outcome of a rare case of lymphoma of the ankle. (J Am Podiatr Med Assoc 100(6): 505–510, 2010)

A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma

2019 ◽  
Vol 25 (8) ◽  
pp. 2041-2044 ◽  
Author(s):  
Hailey Hill ◽  
Justin Arnall ◽  
Amanda Janes ◽  
Crystal Hatley ◽  
Kristen Swift ◽  
...  
Keyword(s):  
B Cell ◽  
Outpatient Clinic ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Outpatient Setting ◽  
Hodgkin's Lymphoma ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

IntroductionSeveral regimens for treating hematologic malignancies are given inpatient due to multiple factors. Many clinicians are evaluating methods to deliver traditionally inpatient regimens in the outpatient setting to increase patient satisfaction, improve access to therapy, and reduce costs. A regimen traditionally administered inpatient, dexamethasone, cytarabine, and cisplatin (DHAP) is a common and effective salvage regimen for relapsed/refractory non-Hodgkin’s lymphoma. DHAX, which substitutes oxaliplatin for cisplatin, has been identified as a reasonable alternative to DHAP and offers the potential for tolerable administration in the outpatient setting as well.Case descriptionA 74-year-old patient with double hit relapsed/refractory diffuse large B cell lymphoma was given rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAX) in our outpatient clinic; however, this regimen is traditionally administered in the inpatient setting. Our main obstacle being cytarabine doses traditionally given 12 h apart. The outpatient regimen given to our patient was rituximab and oxaliplatin on day 1, cytarabine dose one late afternoon on day 2, cytarabine dose two early morning on day 3, and dexamethasone on days 1–4. Doses of oxaliplatin and cytarabine were reduced due to thrombocytopenia experienced with Cycle 1. He did not experience any increased toxicities or complications associated with the regimen moving forward.DiscussionThis illustrates a unique administration of R-DHAX in an infusion center that operates during typical outpatient clinic hours. Both DHAP and DHAX, with or without rituximab, administered in the outpatient setting may be options to consider in relapsed/refractory non-Hodgkin’s lymphoma.

Primary Cutaneous Non-Hodgkin’s Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy

2001 ◽  
Vol 19 (2) ◽  
pp. 398-405 ◽  
Author(s):  
Andreas H. Sarris ◽  
Ira Braunschweig ◽  
L. Jeffrey Medeiros ◽  
Madeleine Duvic ◽  
Chul S. Ha ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

PURPOSE: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin’s lymphoma (PCNHL). PATIENTS AND METHODS: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. RESULTS: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61% ± 7% and survival was 58% ± 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% ± 12% (P = .0003) versus 0% after radiotherapy; survival was 77% ± 12% versus 25% ± 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% ± 11% and survival 70% ± 18%. CONCLUSION: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.

scholarly journals Primary Extranodal Non-Hodgkin's Lymphomas: A Single Center Experience

2016 ◽  
Vol 6 (1) ◽  
pp. 21-30
Author(s):  
Shagufta T. Mufti ◽  
Abdulhadi T. Samman
Keyword(s):  
Saudi Arabia ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

Background: Primary extranodal non-Hodgkin's lymphoma is emerging as a common entity that presents with diverse clinical features, morphology and immunophenotyping patterns. Aim: The aim of this study is to analyze the clinicopathological and immunohistochemical features in patients with primary extranodal non-Hodgkin's lymphoma. Settings and Design: This is a retrospective observational study from pre-recorded hospital data. Materials and Methods: The data of all histologically confirmed patients with non-Hodgkin's lymphoma were retrieved to identify those confirmed as primary extranodal non-Hodgkin's lymphoma among patients attending King Abdulaziz University Hospital, Jeddah, Saudi Arabia over the last 12 years (January 2003 - May 2015). Retrieved data was analyzed with regards to the demography, clinical features, histopathological and immunohistochemical features. Lymphoma of the study group were classified according to World Health Organization classification of lymphomas 2008. Result: A total of 218 patients with histologically confirmed non-Hodgkin's lymphoma were identified. Seventy-nine (36.2%) had primary extranodal non-Hodgkin's lymphoma. The most common age group affected was 20-39 years for both genders. Gastrointestinal system was the most frequently involved system for both genders. Colon was the most common site involved among males, while thyroid and thymus were the most common sites involved among females. Diffuse large B cell lymphoma was the most common histological type. Conclusion: Primary extranodal non-Hodgkin's lymphoma is common in Saudi Arabia affecting males and females almost equally in the third and fourth decades of life, with diffuse large B cell lymphoma being the most common histologic subtype.

Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation

2005 ◽  
Vol 47 (3) ◽  
pp. 333-334 ◽  
Author(s):  
L Novoa-Takara ◽  
A Dincer ◽  
B Kampalath ◽  
P Van Tuinen ◽  
S Hariharan ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorder ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Post Transplant ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

2010 ◽  
Vol 28 (12) ◽  
pp. 2085-2093 ◽  
Author(s):  
Anjali Advani ◽  
Bertrand Coiffier ◽  
Myron S. Czuczman ◽  
Martin Dreyling ◽  
James Foran ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Phase I Study ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Inotuzumab Ozogamicin ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

Purpose Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22+ B-cell non-Hodgkin's lymphoma (NHL). Patients and Methods Inotuzumab ozogamicin was administered intravenously as a single agent once every 3 or 4 weeks at doses ranging from 0.4 to 2.4 mg/m2. Outcomes included MTD, safety, pharmacokinetics, response, progression-free survival (PFS), and overall survival. Results Seventy-nine patients were enrolled. The MTD was determined to be 1.8 mg/m2. Common adverse events at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each). The objective response rate at the end of treatment was 39% for the 79 enrolled patients, 68% for all patients with follicular NHL treated at the MTD, and 15% for all patients with diffuse large B-cell lymphoma treated at the MTD. Median PFS was 317 days (approximately 10.4 months) and 49 days for patients with follicular NHL and diffuse large B-cell lymphoma, respectively. Conclusion Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell NHL, with reversible thrombocytopenia as the main toxicity.

Sign in / Sign up

Export Citation Format

Share Document